Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 2/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 2/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 2/20 | 1.00 |
| ▸ | CDK2 | P24941 | 2/20 | 1.00 |
| ▸ | MAP3K8 | P41279 | 18/20 | 0.80 |
| ▸ | CDK4 | P11802 | 1/20 | 0.72 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5793235 | 1.00 | CDK1 (1.00) | CDK1CCNB1CCNA2CDK2MAP3K8 | |
| SCHEMBL5807851 | 0.88 | CDK1 (0.78) | CDK1CCNB1CCNA2CDK2MAP3K8 | |
| SCHEMBL5787172 | 0.86 | MAP3K8 (0.84) | CDK1CCNB1CCNA2CDK2MAP3K8 | |
| SCHEMBL29777495 | 0.86 | CDK1 (0.75) | CDK1CCNB1CCNA2CDK2MAP3K8 | |
| SCHEMBL28819173 | 0.86 | CDK1 (0.75) | CDK1CCNB1CCNA2CDK2MAP3K8 | |
| SCHEMBL5790267 | 0.86 | CDK1 (0.75) | CDK1CCNB1CCNA2CDK2MAP3K8 | |
| SCHEMBL5790315 | 0.85 | CDK1 (0.74) | CDK1CCNB1CCNA2CDK2MAP3K8 | |
| SCHEMBL31540636 | 0.84 | CDK1 (1.00) | CDK1CCNB1CCNA2CDK2MAP3K8 | |
| SCHEMBL15614971 | 0.84 | CDK1 (1.00) | CDK1CCNB1CCNA2CDK2MAP3K8 | |
| SCHEMBL6502213 | 0.83 | MAP3K8 (0.80) | CDK1CCNB1CCNA2CDK2MAP3K8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4419094-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | Edison Oncology (US) | 2024-08-28 | — | — | EP | claimed |
| WO-2023069727-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | EDISON ONCOLOGY (US) | 2023-04-27 | — | — | WO | claimed |
| US-12491272-B2 | Stable, concentrated radionuclide complex solutions | ADVANCED ACCELERATOR APPLICATIONS SA (FR) | 2025-12-09 | — | — | US | disclosed |
| WO-2025096673-A1 | COMPOSITIONS COMPRISING CELLS TARGETING CANCER AND METHODS OF USING THE SAME | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-119925616-A | CD20 therapy, CD22 therapy and combination therapy with CD19 Chimeric Antigen Receptor (CAR) expressing cells | 诺华股份有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-110461315-B | Treatment and prevention of cytokine release syndrome using chimeric antigen receptor in combination with kinase inhibitors | 诺华股份有限公司 | 2025-05-02 | — | — | CN | disclosed |
| US-20250082791-A1 | Stable, concentrated radionuclide complex solutions | ADVANCED ACCELERATOR APPLICATIONS (ITALY) S.R.L. (IT) | 2025-03-13 | — | — | US | disclosed |
| CN-114555589-B | Compounds and compositions for inhibiting EZH2 | 诺华公司 | 2024-10-25 | — | — | CN | disclosed |
| CN-114746414-B | Aza-quinoline compounds and uses thereof | 诺华公司 | 2024-10-18 | — | — | CN | disclosed |
| EP-4441085-A2 | HIGH SELECTIVE CD229 ANTIGEN BINDING DOMAINS AND METHODS OF USE | University of Utah Research Foundation (US) | 2024-10-09 | — | — | EP | disclosed |
| CN-118726268-A | Methods for improving the efficacy and expansion of chimeric antigen receptor expressing cells | 诺华股份有限公司 | 2024-10-01 | — | — | CN | disclosed |
| CN-114621969-A | Targeted cytotoxic cells with chimeric receptors for adoptive immunotherapy | 诺华股份有限公司 | 2022-06-14 | — | — | CN | disclosed |
| EP-3994132-A1 | TYROSINE KINASE NON-RECEPTOR 1 (TNK1) INHIBITORS AND USES THEREOF | Sumitomo Dainippon Pharma Oncology, Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| CN-114302878-A | Tyrosine kinase non-receptor 1(TNK1) inhibitors and uses thereof | 大日本住友制药肿瘤公司 | 2022-04-08 | — | — | CN | disclosed |
| WO-2022043558-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022043556-A1 | STABLE RADIOPHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022043557-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2022-03-03 | — | — | WO | disclosed |
| CN-114107424-A | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof | 诺华股份有限公司 | 2022-03-01 | — | — | CN | disclosed |
| WO-2022040586-A2 | COMPOSITIONS AND METHODS FOR IN VIVO GENERATION OF CAR EXPRESSING CELLS | NOVARTIS AG (CH) | 2022-02-24 | — | — | WO | disclosed |
| WO-2022033492-A1 | QUINOLINE COMPOUNDS AND COMPOSITIONS FOR INHIBITING EZH2 | NOVARTIS AG (CH) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12491272-B2 | Stable, concentrated radionuclide complex solutions | EPOR, PAICS, XPO5 | CDK1 2920/4885CCNB1 2387/4885CCNA2 2584/4885 |
| US-20250082791-A1 | Stable, concentrated radionuclide complex solutions | EPOR, PAICS, XPO5 | CDK1 2920/4885CCNB1 2387/4885CCNA2 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.